摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-isothiocyanato-butyronitrile | 117500-04-6

中文名称
——
中文别名
——
英文名称
4-isothiocyanato-butyronitrile
英文别名
4-Isothiocyanato-butyronitril;3-Cyan-propylisothiocyanat;4-isothiocyanatobutanenitrile
4-isothiocyanato-butyronitrile化学式
CAS
117500-04-6
化学式
C5H6N2S
mdl
——
分子量
126.182
InChiKey
VRPJLNOXVAKKNU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    68.2
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    4-isothiocyanato-butyronitrile一水合肼 作用下, 以 乙醇 为溶剂, 反应 0.17h, 以99%的产率得到1-Amino-3-(3-cyanopropyl)thiourea
    参考文献:
    名称:
    通过分子内环加成消除反应稠合的1,2,4-噻二唑类的合成4-甲基-5-(氰基拴)亚氨基Δ 2 -1,2,3,4- thiatriazolines
    摘要:
    制备了一系列在亚胺官能团上带有氰基链的5-亚氨基-1,2,3,4-噻唑啉,并通过热解将其转化为稠合的1,2,4-噻二唑衍生物。它们是12a→13、20a→21、20b→22和29→30(方案2-5)。在一种情况下,前体噻三唑还进行了分子内环加成消除反应,得到稠合的1,2,4-噻二唑;即17a→18。具有直接连接到亚胺官能团上的芳基的噻唑啉33被热解到苯并噻唑34上。
    DOI:
    10.1016/s0040-4020(01)90364-3
  • 作为产物:
    描述:
    参考文献:
    名称:
    Bacteriostats. II.1 The Chemical and Bacteriostatic Properties of Isothiocyanates and their Derivatives
    摘要:
    DOI:
    10.1021/ja01525a057
点击查看最新优质反应信息

文献信息

  • Rigidified Compounds for Modulating Heparanase Activity
    申请人:Gelder M. Van Joel
    公开号:US20080039456A1
    公开(公告)日:2008-02-14
    Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.
    揭示了一种新颖的刚性化合物,其具有类似罗丹啉的残基和至少一个连接到类似罗丹啉残基的芳基或杂芳基残基,其中这些化合物的核心结构,如规范中定义的那样,其特征是具有一个或零个可自由旋转的键。还披露了含有这些刚性化合物的药物组合物以及用于调节肝素酶活性的用途,从而治疗与肝素酶相关的疾病和紊乱,并用于调节肝素结合蛋白的活性以及治疗与肝素结合蛋白相关的疾病和紊乱,以及治疗至少部分可通过罗丹啉或罗丹啉类似物治疗的医疗状况的用途。
  • Rigidified compounds for modulating heparanase activity
    申请人:InSight Biopharmaceuticals Ltd.
    公开号:US07795255B2
    公开(公告)日:2010-09-14
    Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.
    本发明揭示了一种新的刚性化合物,该化合物具有类似罗丹明的残基和至少一个与类似罗丹明残基相连的芳基或杂环芳基残基,其中这些化合物的核心结构,如规范中所定义的,其特征是具有一个或零个自由旋转键。本发明还揭示了含有这些刚性化合物的药物组合物,以及利用这些化合物调节肝素酶的活性,从而治疗肝素酶相关疾病和疾病的用途,利用这些化合物调节肝素结合蛋白的活性,从而治疗肝素结合蛋白相关疾病和疾病的用途,以及治疗至少部分可由罗丹明罗丹明类似物治疗的医疗状况的用途。
  • L'abbe, Gerrit; Leurs, Stefan, Journal of the Chemical Society. Perkin transactions I, 1992, # 2, p. 181 - 182
    作者:L'abbe, Gerrit、Leurs, Stefan
    DOI:——
    日期:——
查看更多